503a retatrutide Retatrutide 10mg — Triple Receptor

Read the letter, and learn about this issue on our PBM page

Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia

Body composition effects One concern with any rapid weight loss intervention is the loss of lean mass alongside fat mass

Semaglutide (Ozempic/Wegovy) Timeline Phase 3 trials began: 2015 (SUSTAIN program for diabetes) FDA approval (Ozempic for diabetes): December 2017 Commercial availability: Early 2018 Wegovy (obesity indication) Phase 3: 2018-2020 (STEP program) Wegovy FDA approval: June 2021 Wegovy commercial launch: September 2021, immediately went into shortage due to overwhelming demand Stable widespread availability: Mid-2023 (after Novo Nordisk scaled up manufacturing) Total time from Phase 3 start to stable availability: About 8 years for diabetes indication, 5 years for obesity indication (but with significant supply constraints)

This calculator is intended for injectable semaglutide supplied in a vial with a concentration written in mg/mL